Company Name: Cellectis S.A.

Cellectis is engaged in gene editing. The company develops immune-oncology products based on gene edited Chimeric Antigen Receptors (CAR) T-cells.

Ticker Symbol: CLLS (NASDAQ)

Company Website: www.cellectis.com

Social Media:

Cellectis Facebook

Cellectis LinkedIn

Cellectis Twitter

Cellectis YouTube

Headquarters: Paris, France